Compare ITP & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITP | BIAF |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | China | United States |
| Employees | N/A | 57 |
| Industry | Paper | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.6M |
| IPO Year | 2020 | N/A |
| Metric | ITP | BIAF |
|---|---|---|
| Price | $0.19 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 168.1K | ★ 226.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,837,943.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.16 |
| 52 Week High | $1.00 | $13.50 |
| Indicator | ITP | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 47.36 |
| Support Level | $0.17 | $0.90 |
| Resistance Level | $0.22 | $1.45 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 43.30 | 28.57 |
IT Tech Packaging Inc is a holding company engaged in the business of paper manufacturing in China. The company operates as a producer and distributor of paper products. It is involved in the production and distribution of three categories of paper products: packing paper (corrugating medium paper), offset printing paper, and tissue paper products. It also produces digital photo paper. Its business is structured into three segments: Dongfang Paper and Tengsheng Paper, which produce offset printing paper, corrugating medium paper, and tissue paper, and Baoding Shengde, which produces face masks and digital photo paper.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.